Wire · opportunities
OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
OmniAb presented its AI-enhanced antibody discovery platform combining transgenic animals and AI screening tools, highlighting a $3 billion milestone pipeline with 110 pharmaceutical partners. The company focuses on licensing technology to pharma and biotech firms rather than internal drug development, projecting revenue growth from instrument sales and partner milestones.
This Wire brief sits within Fusion42's coverage of Biotech, AI Frontier Models and Drug Discovery.
◆ ◆ The Wire takeaway
You now face a biotech model that sells AI-enhanced discovery tools, not drugs, shifting your sales focus from end products to platform licensing and milestone revenue. Consider partnerships for xPloration instruments and licensing to capture recurring income beyond traditional drug development.
◆ Coverage
1 source · 25 Oct 2026
◆ Related on Wire
◆ Topics